Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Durian

Showing results (141-150 of 156) with videos related to

Pageof 16
Sort By:
Journal of Thrombosis and Haemostasis : JTH|January 23, 2013
Hestia criteria can safely select patients with pulmonary embolism for outpatient treatment irrespective of right ventricular functionW Zondag, L M A Vingerhoets, M F Durian, et al.
Thrombosis and Haemostasis|May 29, 2015
Thromboembolic resolution assessed by CT pulmonary angiography after treatment for acute pulmonary embolismPaul L den Exter, Josien van Es, Lucia J M Kroft, et al.
The Review of Scientific Instruments|January 1, 2022
Soft matter dynamics: A versatile microgravity platform to study dynamics in soft matterP Born, M Braibanti, L Cristofolini, et al.
Annals of Internal Medicine|June 8, 2011
Performance of 4 clinical decision rules in the diagnostic management of acute pulmonary embolism: a prospective cohort studyRenée A Douma, Inge C M Mos, Petra M G Erkens, et al.
The Review of Scientific Instruments|August 3, 2018
An instrument for studying granular media in low-gravity environmentS Aumaître, R P Behringer, A Cazaubiel, et al.
The Lancet. Oncology|January 12, 2019
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup studyJacoline E C Bromberg, Samar Issa, Katerina Bakunina, et al.
Neuro-Oncology|December 1, 2023
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 studyJacoline E C Bromberg, Samar Issa, Bronno van der Holt, et al.
Haematologica|September 14, 2019
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 studyLene Kongsgaard Nielsen, Claudia Stege, Birgit Lissenberg-Witte, et al.
JAMA|March 20, 2014
Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE studyMarc Righini, Josien Van Es, Paul L Den Exter, et al.
European Journal of Haematology|February 17, 2025
Treatment-Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML PatientsC Kockerols, P J M Valk, P Hogenbirk, et al.
Pageof 16

Showing results (141-150 of 156) with videos related to

Sort By:
Pageof 16
Journal of Thrombosis and Haemostasis : JTH|January 23, 2013
Hestia criteria can safely select patients with pulmonary embolism for outpatient treatment irrespective of right ventricular functionW Zondag, L M A Vingerhoets, M F Durian, et al.
Thrombosis and Haemostasis|May 29, 2015
Thromboembolic resolution assessed by CT pulmonary angiography after treatment for acute pulmonary embolismPaul L den Exter, Josien van Es, Lucia J M Kroft, et al.
The Review of Scientific Instruments|January 1, 2022
Soft matter dynamics: A versatile microgravity platform to study dynamics in soft matterP Born, M Braibanti, L Cristofolini, et al.
Annals of Internal Medicine|June 8, 2011
Performance of 4 clinical decision rules in the diagnostic management of acute pulmonary embolism: a prospective cohort studyRenée A Douma, Inge C M Mos, Petra M G Erkens, et al.
The Review of Scientific Instruments|August 3, 2018
An instrument for studying granular media in low-gravity environmentS Aumaître, R P Behringer, A Cazaubiel, et al.
The Lancet. Oncology|January 12, 2019
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup studyJacoline E C Bromberg, Samar Issa, Katerina Bakunina, et al.
Neuro-Oncology|December 1, 2023
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 studyJacoline E C Bromberg, Samar Issa, Bronno van der Holt, et al.
Haematologica|September 14, 2019
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 studyLene Kongsgaard Nielsen, Claudia Stege, Birgit Lissenberg-Witte, et al.
JAMA|March 20, 2014
Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE studyMarc Righini, Josien Van Es, Paul L Den Exter, et al.
European Journal of Haematology|February 17, 2025
Treatment-Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML PatientsC Kockerols, P J M Valk, P Hogenbirk, et al.
Pageof 16